Goldman Sachs Initiates Coverage On Pacific Biosciences with Buy Rating, Announces Price Target of $17
Portfolio Pulse from richadhand@benzinga.com
Goldman Sachs has initiated coverage on Pacific Biosciences with a Buy rating and has announced a price target of $17.

June 30, 2023 | 9:18 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Goldman Sachs has initiated coverage on Pacific Biosciences with a Buy rating, which could potentially increase investor interest and drive the stock price up.
Analyst ratings often influence investor sentiment. A Buy rating from a reputable firm like Goldman Sachs indicates a positive outlook for the company, which could lead to increased demand for the stock and potentially drive the price up. The price target of $17 also suggests that Goldman Sachs believes the stock is undervalued at its current price, which could further stimulate buying interest.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100